ATE320265T1 - Staphylococcus-antigene und impstoff - Google Patents

Staphylococcus-antigene und impstoff

Info

Publication number
ATE320265T1
ATE320265T1 AT00916405T AT00916405T ATE320265T1 AT E320265 T1 ATE320265 T1 AT E320265T1 AT 00916405 T AT00916405 T AT 00916405T AT 00916405 T AT00916405 T AT 00916405T AT E320265 T1 ATE320265 T1 AT E320265T1
Authority
AT
Austria
Prior art keywords
antigen
staphylococcus
strains
carry
vaccine
Prior art date
Application number
AT00916405T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Ibrahim Fattom
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of ATE320265T1 publication Critical patent/ATE320265T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00916405T 1999-03-19 2000-03-17 Staphylococcus-antigene und impstoff ATE320265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/272,359 US6936258B1 (en) 1999-03-19 1999-03-19 Staphylococcus antigen and vaccine

Publications (1)

Publication Number Publication Date
ATE320265T1 true ATE320265T1 (de) 2006-04-15

Family

ID=23039462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916405T ATE320265T1 (de) 1999-03-19 2000-03-17 Staphylococcus-antigene und impstoff

Country Status (15)

Country Link
US (2) US6936258B1 (de)
EP (1) EP1162997B1 (de)
JP (1) JP4656728B2 (de)
AT (1) ATE320265T1 (de)
AU (1) AU773226B2 (de)
BR (1) BR0009157B1 (de)
CA (1) CA2366433C (de)
CY (1) CY1105500T1 (de)
DE (1) DE60026691T2 (de)
DK (1) DK1162997T3 (de)
ES (1) ES2261192T3 (de)
MX (1) MXPA01009476A (de)
NZ (1) NZ514455A (de)
PT (1) PT1162997E (de)
WO (1) WO2000056357A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2469714A1 (en) * 2001-12-21 2003-07-24 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
KR101302764B1 (ko) 2005-06-13 2013-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 포도상구균 감염을 치료 및 예방하기 위한 팬톤-발렌타인류코시딘의 용도
WO2007008904A2 (en) * 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
EP2368569A3 (de) 2006-01-18 2012-05-02 University Of Chicago Zusammensetzungen und Verfahren im Zusammenhang mit Proteinen des Staphylococcus-Bakteriums
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
MX2008015814A (es) 2006-06-12 2009-01-12 Nabi Biopharmaceuticals Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
EP2185190B1 (de) 2007-08-31 2015-06-24 University Of Chicago Verfahren und zusammensetzungen zur immunisierung gegen durch staphylokokken vermittelte lungenerkrankungen und -leiden
BRPI0920041A2 (pt) 2008-10-06 2017-06-27 Univ Chicago composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
ES2729934T3 (es) 2009-06-22 2019-11-07 Wyeth Llc Composiciones y procedimientos para preparar composiciones inmunogénicas de conjugado de polisacárido capsular de serotipo 8 de Staphylococcus aureus
AR078601A1 (es) 2009-06-22 2011-11-23 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
MX338753B (es) 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
ES2626416T3 (es) 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purificación de sacáridos capsulares de Staphilococcus aureus de tipo 5 y de tipo 8
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
US8821894B2 (en) 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
MX350170B (es) 2010-12-22 2017-08-28 Wyeth Llc Composición inmunogénica estable de antígenos de staphylococcus aureus.
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
EP2814803A4 (de) 2011-12-14 2015-11-11 Indicator Systems International Inc Trisubstituierte methylalkohole und polymerisierbare derivate daraus
WO2013162751A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP3805395A1 (de) 2012-04-26 2021-04-14 University Of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
DK3421051T3 (da) 2012-08-16 2020-06-22 Pfizer Fremgangsmåder til glycokonjugering og sammensætninger
CA2943263C (en) 2012-12-20 2018-12-04 Pfizer Inc. Glycoconjugation process
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3957321A3 (de) 2014-01-21 2022-07-13 Pfizer Inc. Kapsulare polysaccharide aus streptococcus pneumoniae und konjugate davon
MX371453B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
MX368897B (es) 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3952906A1 (de) 2019-04-10 2022-02-16 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
EP0648127B1 (de) 1991-11-22 2003-04-16 Univax Biologics Incorporated Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
AU5804198A (en) 1996-12-20 1998-07-17 Research Foundation Of The City University Of New York A novel pathogenic coccoid organism, (staphylococcus leei), with trophism for gastric mucin
US5965374A (en) * 1997-10-16 1999-10-12 Biowhittaker Technologies, Inc. Glucan-specific assay
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
PT1121135E (pt) * 1998-09-14 2009-03-05 Nabi Biopharmaceuticals Composições de b-glucanos e de imunoglobulinas específicas
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations

Also Published As

Publication number Publication date
ES2261192T3 (es) 2006-11-16
JP4656728B2 (ja) 2011-03-23
MXPA01009476A (es) 2003-08-19
DE60026691D1 (de) 2006-05-11
JP2002539272A (ja) 2002-11-19
BR0009157B1 (pt) 2013-12-24
AU3751300A (en) 2000-10-09
WO2000056357A3 (en) 2001-02-01
US7531633B2 (en) 2009-05-12
PT1162997E (pt) 2006-07-31
US20050118190A1 (en) 2005-06-02
EP1162997B1 (de) 2006-03-15
NZ514455A (en) 2003-11-28
AU773226B2 (en) 2004-05-20
BR0009157A (pt) 2002-04-16
DE60026691T2 (de) 2006-09-07
US6936258B1 (en) 2005-08-30
CA2366433C (en) 2012-01-03
EP1162997A2 (de) 2001-12-19
CY1105500T1 (el) 2010-04-28
DK1162997T3 (da) 2006-07-17
WO2000056357A2 (en) 2000-09-28
CA2366433A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
ATE320265T1 (de) Staphylococcus-antigene und impstoff
DK1178824T3 (da) Staphylococcus aureus-antigenholdig helcellevaccine
ATE414532T1 (de) Staphylococcus aureus antigen
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
EP2261358A3 (de) Streptokokken-Antigene
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DK0648127T3 (da) Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis
AP2000001886A0 (en) Group B streptococcus antigens.
ATE314462T1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE445839T1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
AR022237A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
ES2088464T3 (es) Uso y administracion de enzimas.
ATE315649T1 (de) Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung
NO20022276L (no) Placental human neurokinin-B-forlöper
ATE206138T1 (de) Helicobacter pylori antigen
CO5241277A1 (es) Vacuna
DE69424054D1 (de) Verwendung von antikörpern gegen beta-2-mikroglobulin-freie klasse-i-hla-molekülen zum erhalt eines diagnostischen hiv-tests und zusammensetzungen mit schutzwirkung gegen hiv-infektionen
UA37623A (uk) Спосіб одержання сироватки проти стрептококових та стафілококових інфекцій у тварин

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1162997

Country of ref document: EP

EEIH Change in the person of patent owner